Latest pharma industry updates by Nicolas Schmitz

Nicolas Schmitz, Senior Manager, Strategic Market Analyst at KBI Biopharma, shared a post on LinkedIn:

“Latest pharma industry updates:

• Pharma stocks globally faced a challenging 2023, with only anti-obesity Eli Lilly and Company and Novo Nordisk shining.
• Goldman Sachs closes a $650M fund for life sciences investments, one of the largest first-time private funds in the sector.
• Longboard Pharmaceuticals shares surge 316% after promising data from bexicaserin study for developmental and epileptic encephalopathies.
• Esperion amends collaboration with Daiichi Sankyo, Inc. resolving disputes with a $125 million agreement.
• Roche partners with Remix Therapeutics, exploring new RNA-targeting drugs, the third such deal following Arrakis and Ribometrix.
• Pfizer secures Canadian approval for its first gene therapy, Beqvez, for hemophilia B.
• Eli Lilly and Company launches “LillyDirect,” an online service in the U.S. for obesity, migraine, and diabetes treatments, including delivery and telehealth support.
• Dermata Therapeutics, Inc. shares rise 113% after securing a new patent in Japan for DMT410 in hyperhidrosis treatment.
• Novo Nordisk announces research partnerships with Omega Therapeutics and Cellarity for obesity and NASH treatments.
• Boehringer Ingelheim collaborates with Ribocure Pharmaceuticals AB to develop RNAi-based liver disease treatments, including NASH.
• Merck CEO Robert Davis highlights GLP-1 treatments with benefits beyond weight loss, citing efinopegdutide’s potential in NASH.
• Evotec CEO Werner Lanthaler resigns after a challenging year, leading to a 20% drop in company’s stock.
• Innate Pharma’s lacutamab trial resumes post-FDA investigation into a patient’s death.
• Allogene Therapeutics plans strategic shift to improve CAR-T therapy use in earlier treatment stages.
• Lykos Therapeutics (formerly MAPS PBC) raises over $100M for MDMA-based PTSD therapy, eyeing FDA approval.
• Intellia Therapeutics, Inc. announces layoffs and research cuts, focusing on priority drug programs.
• Roche signs $50M ADC deal with a Chinese biotech, continuing its expansion in the field.
• Roche secures a $66M deal with MOMA Therapeutics, the third significant pact of the week
• Nemaura Pharma Limited opts for delisting from Nasdaq, moving to OTC Markets, with shares falling 32%.”

Source: Nicolas Schmitz/LinkedIn